
Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the company. AKC will act in a business advising, investment banking, management and strategy role to support and advance IVRO's previously announced corporate growth plan. AKC will provide executive and organizational support, including strategy refinement, planning and operational review & more where needed & appropriate.
IVRO CEO, W. Richard Ulmer, said: "InVitro believes it is adapting well to post-Covid '19 & inflationary times by adding guidance from experienced minds with an outstanding past performance record. We are delighted to have met and now partnered with Ron Askew and his team in this final month of our Fiscal '24 Year."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221834
SOURCE: InVitro International